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Abstract
Background: We evaluated the clinical significance and prognostic value of histopathological features of bladder
cancer, such as subepithelial growth patterns and tumor growth pattern at the invasion front.
Methods: In total, 130 patients newly diagnosed with non-muscle invasive bladder cancer and underwent
transurethral resection between 1998 and 2009 were enrolled. Subepithelial growth patterns consisting of
endophytic growth pattern (EGP) and von Brunn’s nest involvement (VBNI) were investigated using hematoxylin
and eosin-stained slides, and their frequency of occurrence, prognostic value, and correlation with other
clinicopathological features was evaluated.
Results: EGP and VBNI were found in 40 (30.8%) and 5 (3.9%) of the 130 cases, respectively. Of the 26 pT1 tumors,
the growth pattern at the invasion front was trabecular in 17 (65.4%) and infiltrative in 9 (34.6%). Although 8
(47.1%) of 17 trabecular tumors coexisted with EGP, no cases with infiltrative tumors had EGP (p = 0.023). VBNI
correlated with high tumor grades (p = 0.006) and lymphovascular involvement (p = 0.026). The multivariate Cox
proportional hazards analysis revealed that tumor diameter less than 3 cm (p = 0.04) and intravesical bacillus
Calmette-Guérin therapy (p = 0.004) were independent favorable prognostic factors for recurrence-free survival,
whereas tumor stage was an independent poor prognostic factor for disease progression (p = 0.006).
Conclusions: Subepithelial growth patterns were not a significant prognostic factor in this study. Additionally, no
tumors with an infiltrative growth pattern coexisted with EGP, suggesting that determining the presence of EGP
might be helpful for managing non-muscle invasive bladder cancers.
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Background
Urothelial carcinoma (UC) of the bladder is a malignant
neoplasm characterized by heterogenous cell popula-
tions and divergent clinical outcomes. Approximately
70% of newly diagnosed bladder cancers are non-muscle
invasive bladder cancers (NMIBCs) (pTa-1 or pTis), for
which the initial treatment is trans-urethral resection of
bladder tumor (TURBT). However, 50-70% of these
patients experience intravesical recurrence within 5
years, and almost 10% progress to muscle invasive (≥
pT2) or metastatic disease [1]. In the management of
NMIBC, standard clinicopathological criteria have been
used to assess the risk of intravesical recurrence and dis-
ease progression. A recent study by Gofrit et al. demon-
strated that subepithelial growth patterns are found
predominantly in high-gradea n dh i g h - s t a g eb l a d d e r
cancers and are associated with poor prognosis [2]. Sub-
epithelial growth patterns in bladder cancer consist of
endophytic growth pattern (EGP) and von Brunn’sn e s t
involvement (VBNI).
Although most papillary urothelial carcinomas are
characterized by an exophytically growing tumor; some
exhibit an EGP and subepithelial growth pattern. A
study by Amin et al. reported detailed morphological
descriptions of 18 cases of UC with EGP and reviewed
the problems associated with assessment of tumor inva-
sion [3]. At present, there is little data on the frequency
and prognostic significance of EGP [2,3]. Von Brunn’s
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p r o p r i at h a th a v eb e c o m ed e t a c h e df r o mt h eo v e r l y i n g
epithelium [4]. These nests have been commonly identi-
fied in 80-90% of normal bladders in autopsy studies
[4,5]. A retrospective study demonstrated that VBNI
lesions occurred in 73/371 (19.1%) patients with
NMIBC, and its presence was not a risk factor for dis-
ease progression nor an absolute indication for radical
cystectomy [5]. However, since the first report describ-
ing VBNI by Seemayer et al. [6], there have been very
few reports on its clinical significance [2,5].
In bladder pathology, molecular mimicry between the
subepithelial growing tumor and the tumor invading the
lamina propria exists. Both of subepithelial growing pat-
terns and appearance of invasion to the lamina propria
are morphologically pushing into the stromal tissue.
Thus, we aimed to investigate the association between
EGP or VBNI and the tumor growth pattern at the inva-
sion front (hereafter referred to as “growth pattern”).
According to the classification by Jiminez et al. [7], 3
growth patterns were detected: “nodular” (composed
mostly of well delineated, round nests of tumor cells);
“trabecular” (composed of broad trabeculae, which
usually anastomosed with each other); and “infiltrative”
(composed of infiltrating narrow cords or single cells).
Growth pattern has been reported to be a poor prognos-
tic factor, both in MIBC and NMIBC [7-10].
In the present study, we retrospectively reviewed the
records of 130 patients with newly diagnosed NMIBC in
order to elucidate the clinical relevance of subepithelial
growth patterns. In pT1 tumors, the association between
tumor growth pattern at the invasion front and sube-
pithelial growth pattern was also analyzed.
Methods
Patients and pathological review
An institutional database was obtained from the Hirao
Hospital registry, and archived data on patients newly
diagnosed with NMIBC between July 1998 and Novem-
ber 2009 were reviewed. All of the patients were ethni-
cally Japanese. Patients with concomitant urothelial
carcinoma of the upper urinary tract or nonurothelial
carcinoma histology were excluded. All hematoxylin and
eosin-stained slides were reviewed by a single uropathol-
ogist (K.S.) for staging (according to the TNM system)
[11]; grading (according to the 2004 WHO classifica-
tion) [12]; presence of EGP, VBNI, carcinoma in situ
(CIS) and lymphovascular involvement (LVI); and deter-
mination of the growth pattern in the 26 cT1 tumors.
Tumors were classified into papillary urothelial neo-
plasm with low malignant potential (PUNLMP), low
grade (LG), and high grade (HG). EGP was defined as
the presence of either broad bulbous tongues of neo-
plastic urothelial cells in the presence or absence of
stromal reaction extending deep into the lamina propria
but not into the muscularis propria or endophytic
expansile growth with or without peripheral palisading
of basal cells [3]. The use of clinicopathological informa-
tion was approved by the Local Commission for Medical
Ethics and Clinical Studies.
Follow-up after initial TURBT
Clinical information and follow-up data were collected
by chart review. Adjuvant intravesical instillation therapy
after the initial TURBT was administered to 75 patients.
Of these, 67 received intravesical instillation of bacillus
Calmette-Guérin (BCG) 6 or 8 times at a dose of 80
mg. The remaining 8 patients received intravesical instil-
lation of an anthracycline antitumor drug, epirubicin, 30
times at a dose of 20 or 40 mg. Follow-up management
was relatively uniform. The patients were monitored by
routine cystoscopy and urine cytology at 3-month inter-
vals during the first 3 years, every 6 months during the
following 2 years, and thereafter once every year. Abdo-
minopelvic computerized tomography and chest radio-
graphy were performed at 6- to 12-month intervals.
Recurrence was defined as the histological diagnosis of a
tumor in the urinary bladder after surgical resection.
Progression was defined as the detection of a muscle-
invasive disease (≥ pT2) in the urinary bladder or a
metastatic site in other organs by histological diagnosis
and/or diagnostic imaging.
Statistical analysis
Dr. SPSS II version 11.0.1 for Windows (SPSS Inc., Chi-
cago, IL, USA) and PRISM software version 4.00 (San
Diego, CA, USA) were utilized for statistical analyses
and plotting the data, respectively. A p value of < 0.05
was considered statistically significant. Correlation
among the clinicopathological variables was analyzed
using the chi-square test of association. Recurrence-free
and progression-free survival curves were obtained using
the Kaplan-Meier method, a n dc o m p a r e db yt h el o g
rank test for each prognostic variable. Multivariate ana-
lysis was performed to identify independent prognostic
variables using a stepwise Cox proportional hazards
regression model. For multivariate analysis, variables
were selected on the condition that they were statisti-
cally significant in the univariate analysis.
Results
Correlation between subepithelial growth patterns and
other clinicopathological parameters
EGP and VBNI were found in 40/130 (30.8%) and 5/130
(3.9%) patients, respectively (Figure 1). We determined
the association of EGP and VBNI with various clinico-
pathological parameters (Table 1). VBNI correlated with
high tumor grade (p = 0.006) and the presence of LVI
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Page 2 of 9(p = 0.026), whereas EGP did not correlate with any of
the parameters analyzed. The growth pattern was trabe-
cular in 17/26 (65.4%) and infiltrative in 9/26 (34.6%)
pT1 tumor patients. It is significant that no tumor with
an infiltrative growth pattern coexisted with EGP. In
contrast, 8/17 (47.1%) tumors with a trabecular growth
pattern were found to coexist with EGP (p = 0.023).
Analyses of prognostic parameters for intravesical tumor
recurrence and disease progression
To examine the relevance of subepithelial growth pat-
terns in disease outcome, we performed univariate and
multivariate analyses using prognostic parameters. The
median follow-up period was 36 months (range: 1 to
140 months). In all, 41/130 (31.5%) and 6/130 (4.6%)
patients experienced recurrence and progression,
respectively. The univariate analysis for tumor recur-
rence revealed that multiplicity (p = 0.038) and tumor
diameter ≥ 3 cm (p = 0.023) were significant predictors
of a high recurrence rate, and that intravesical BCG
therapy (p = 0.039) decreased the recurrence rate (Table
2). The multivariate Cox proportional hazards analysis
revealed that both, tumor diameter < 3 cm (p = 0.04)
and intravesical BCG therapy (p = 0.004) were indepen-
dent favorable prognosis parameters of recurrence-free
survival (Table 2). Upon evaluating factors associated
with disease progression, the univariate analysis demon-
strated that stage (p < 0.0001), tumor grade (p =
0.0013), LVI (p = 0.0002), and tumor diameter ≥ 3c m
(p = 0.0004) were significantly associated with a poor
prognosis (Table 3). Among these, stage was the only
independent factor associated with disease progression
100  m 500  m
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A
B
Figure 1 Representative pathological findings with subepithelial growth patterns. (A) An endophytic growth pattern (black arrowheads) is
observed with a low-grade papillary growing tumor. (B) A high-grade tumor with Brunn’s nests. Carcinoma in situ is seen on the surface
epithelium (red arrowheads). The right panel represents a magnification of the box marked in the left panel.
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Page 3 of 9Table 1 The association between subepithelial growth patterns and various parameters
Variables Cases (n) Subepithelial growth pattern
Endophytic growth pattern von Brunn’s nests involvement
Absent Present Present (%) p value Absent Present Present (%) p value
Total 130 90 40 30.8 - 125 5 4.0 -
Age (years) 0.56 0.66
< 70 55 35 20 36.4 52 3 5.5
≥70 65 45 20 30.8 63 2 3.1
Gender 0.96 1.00
M 114 79 35 30.7 109 5 4.4
F 16 11 5 31.3 16 0 0.0
T stage 1.00 0.054
a 104 72 32 30.8 102 2 1.9
1 26 18 8 30.8 23 3 11.5
Tumor grade (2004 WHO) 0.70 0.006
PUNLMP 13 10 3 23.1 13 0 0.0
LG 84 55 29 34.5 83 1 1.2
HG 33 25 8 24.2 25 4 12.1
Concomitant CIS 0.054 0.26
absent 123 73 40 35.4 109 4 3.5
present 7 7 0 0.0 6 1 14.3
Lymphovascular involvement 0.94 0.026
absent 110 76 34 30.9 108 2 1.8
present 20 14 6 30.0 17 3 15.0
Tumor growth pattern 0.023 0.53
(pT1, n = 26) trabecular 17 9 8 47.1 14 3 17.6
infiltrative 9 9 0 0.0 9 0 0.0
Endophytic growth pattern 0.64
absent 90 - - - 87 3 3.3
present 40 - - - 38 2 5.0
von Brunn’s nest involvement 0.64
absent 125 87 38 30.4 - - -
present 5 3 2 40.0 - - -
Multiplicity 0.33 0.66
solitary 70 51 19 27.1 68 2 2.9
multiple 60 39 21 35.0 57 3 5.0
Tumor diameter (cm) 0.17 0.59
< 3 99 80 28 28.3 96 3 3.0
3 ≤ 31 19 12 38.7 29 2 6.5
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Page 4 of 9(p = 0.006, Table 3). However, the number of disease
progression events was too small for multivariate
analysis.
In the 26 pT1 tumors, EGP was associated with the
growth pattern typical of less aggressive tumors (Table
1), suggesting that EGP may be a favorable prognostic
factor in patients with a pT1 tumor. We performed
prognostic analyses in a subset of pT1 tumors using the
Kaplan-Meier method and log-rank test. Neither the
growth pattern nor EGP was associated with recur-
rence-free survival rate (Figure 2A and 2B). In the
absence of EGP, there was a tendency toward disease
progression, and an infiltrative growth pattern was asso-
ciated with a high risk of progression (Figure 2C and
2D). Growth patterns were the only significant predic-
tors of progression.
Discussion
In the management of NMIBC, standard clinicopatholo-
gical criteria such as multiplicity, tumor diameter, prior
recurrence rate, T stage, tumor grade, and presence of
concomitant CIS have been used to assess the risk of
Table 2 Univariate and multivariate analysis of intravesical tumor recurrence
Variables Cases (n) Tumor recurrence
Univariate Multivariate
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
T stage
a 104 1 -
1 26 1.40 (0.68-3.21) 0.32
Tumor grade (2004 WHO) 0.14
PUNLMP 13 1 -
LG 84 1.41 (0.50-4.00) 0.57
HG 33 2.17 (0.70-5.56) 0.2
Concomitant CIS
absent 123 1 -
present 7 1.32 (0.36-5.28) 0.20
Lymphovascular involvement
absent 110 1 -
present 20 1.75 (0.86-4.93) 0.11
Endophytic growth pattern
absent 90 1 -
present 40 0.76 (0.39-1.52) 0.45
von Brunn’s nest involvement
absent 125 1 -
present 5 1.54 (0.29-9.94) 0.54
Multiplicity
solitary 70 1 - 1 -
multiple 60 1.91 (1.04-3.59) 0.038 1.93 (0.98-3.79) 0.058
Tumor diameter (cm)
< 3 9 91-1-
≥ 3 31 2.04 (1.13-5.06) 0.023 2.10 (1.04-4.27) 0.040
Intravesical therapy
None 55 1 - 1 -
BCG 67 0.53 (0.23-0.96) 0.039 0.35 (0.18-0.71) 0.004
Anthracyclines 8 0.96 (0.28-3.21) 0.94 0.63 (0.24-2.38) 0.63
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Page 5 of 9intravesical recurrence and progression to MIBC [13,14].
Histopathological features of UC including subepithelial
growth patterns and tumor growth pattern at the inva-
sion front are additional prognostic factors. In the pre-
sent study, we have investigated the frequency and
prognostic relevance of subepithelial growth patterns
and tumor growth patterns in 130 cases with NMIBC.
To our knowledge, this is the first study to analyze
these histopathological variants.
A higher rate of EGP has been reported in high-grade
tumors as compared to low-grade tumors [2]. In our
cohort, there was no significant correlation between
EGP and tumor grade. Moreover, we found a higher
incidence of EGP as compared to that reported by
Gofrit et al. (30.8% vs. 11.9%). Several factors can
account for this discrepancy. Artifact from difference in
pathologic interpretation cannot be ruled out and
further analysis on confirmatory review by a secondary
pathologist would be requi r e d .I na d d i t i o n ,v a r i o u s
environmental factors are associated with carcinogenesis
of bladder cancer and the degree of exposure to these
environmental carcinogens may vary in different coun-
tries and cultures [15]. Moreover, susceptibility to carci-
nogens also depends on genetic background and such
differences could contribute to carcinogenesis of bladder
cancer and the subsequent discrepancy in the incidence
Table 3 Univariate and multivariate analysis for disease progression
Variables Cases (n) Disease progression
Univariate Multivariate
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
T stage
a 104 1 - 1 -
1 26 20.69 (7.82-446.23) < 0.0001 20.94 (2.44-179.45) 0.006
Tumor grade (2004 WHO)
PUNLMP/LG 97 1 - 1 -
HG 33 14.37 (3.25-126.40) 0.0013 2.97 (0.098-90.16) 0.53
Concomitant CIS
absent 123 1 -
present 7 ND 0.51
Lymphovascular involvement
absent 110 1 - 1 -
present 20 12.07 (7.49-733.68) 0.0002 1.23 (0.13-11.28) 0.86
Multiplicity
solitary 70 1 -
multiple 60 5.44 (0.84-20.60) 0.082
Tumor diameter (cm)
<3 9 9 1 - 1 -
≥ 3 31 16.93 (4.63-209.78) 0.0004 6.77 (0.69-66.8) 0.10
Endophytic growth pattern
absent 90 1 -
present 40 ND 0.096
von Brunn’s nest involvement
absent 125 1 -
present 5 5.82 (0.74-5617.98) 0.068
Intravesical therapy
None 55 1 -
BCG 75 1.09 (0.20-5.99) 0.92
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Page 6 of 9of EGP. Additionally, in contrast to the previous reports
[2], EGP was not identified as a significant indicator of
tumor recurrence or progression. However, it is interest-
ing to note that EGP was associated with the tumor
growth pattern at the invasion front in pT1 tumors
(Table 2). Jimenez et al. were the first to report that the
infiltrative growth pattern of MIBC was associated with
poor survival [7]. Recently, Denzinger et al. reported
that the growth pattern in a series of pT1G3 tumors
was a strong predictor of cancer-specific survival and
could thus be important in planning therapeutic strate-
gies [10]. Similarly, our data revealed that the infiltrative
growth pattern was related to worse progression-free
survival as compared to the trabecular growth pattern
(Figure 2C). Although there was no statistical signifi-
cance in the recurrence- and progression-free survival
between tumors with and without EGP, it was a notable
finding that none of the tumors with EGP underwent
disease progression (Figure 2D). Further studies are war-
ranted to clarify the potential prognostic power of EGP
in pT1 tumors.
The infiltrative growth pattern is characterized by sin-
gle cell infiltration of the invasive front of tumors, possi-
bly due to a loss of cell cohesion. In other malignant
diseases, a loss of adhesional markers was seen in the
epithelial mesenchymal transition (EMT) phenomenon,
associated with poor prognosis [16]. Initial studies on
EMT in bladder cancer suggested that low levels of the
adhesion molecules plakoglobin and b-catenin were
related to worse prognosis [17]. Thus, we suggest that
tumors with EGP may have a tendency to retain the
expression and function of the adhesion molecules.
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Figure 2 Kaplan-Meier curves for intravesical recurrence (A, B) and disease progression (C, D) of patients with pT1 tumors (n = 26).A
comparison of tumor growth patterns at the tumor invasion front, trabecular vs. infiltrative and presence vs. absence of endophytic growth
pattern (EGP) is displayed. The numbers at risk are shown below each graph.
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Page 7 of 9present in only 3.9% of our subjects: in 1/83 (1.2%) LG
tumors, 4/25 (12.1%) HG tumors, and none of the 13
PUNLMP cases (p = 0.006, Table 1). VBNI was signifi-
cantly correlated with high tumor grade. There are con-
flicting reports on the prognostic value of VBNI in
disease progression [2,5]. We could not confirm any of
the previous findings due to the small number of sub-
jects with VBNI. In our study, of the 5 cases with VBNI,
1 received no adjuvant treatment and experienced intra-
vesical tumor recurrence a year after the initial TURBT.
Of the 4 patients that received intravesical BCG treat-
ment, 3 showed neither recurrence nor progression dur-
ing the follow-up duration. However, 1 patient
experienced disease progression, wherein the tumor
extended into the prostatic duct 4 years after the initial
TURBT. For this case, an early radical cystectomy
would be the optimal treatment. However, the clinical
relevance of VBNI as a prognostic marker and therapeu-
tic guide remains unclear.
There are several limitations in our study. Our results
were based on the retrospective analysis from a small
number of patients. In particular, the numbers of
patients who experienced disease progression, total
cystectomy or cancer-specific death were too low to
generate an accurate analysis. The prognostic signifi-
cance of subepithelial growth patterns were not com-
pared to cancer-specific survival and overall survival in
our study. Additionally, since the recognition degree of
EGP is considered low by both urologists and patholo-
gists of our country, the difference in pathologic inter-
pretation could affect our results. Therefore,
confirmatory pathologic reviews should be established to
consolidate the entity and clinical significance of EGP.
Conclusions
Subepithelial growth patterns were not a significant
prognostic factor in this study. Considering that no
tumors with an infiltrative growth pattern coexisted
with EGP, determining the presence of EGP might be
helpful for managing NMIBC. Our report would provide
an opportunity for researchers to promote the further
evaluation of EGP and VBNI. Therefore, large-scale stu-
dies and prospective clinical trials are necessary to con-
firm the clinical significance of these pathologic features.
We believe that validation studies on subepithelial
growth patterns will aid in the prognosis and treatment
of urothelial cell cancers.
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